Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Edifice Health, Inc. is an American company located in San Mateo, CA, that provides health care services. It was founded by Mark M. Davis and David Furman.\nThe company says this about itself: Edifice Health is a digital health spin-out company from a 10-year Stanford research in human immunology offering a novel metric of inflammatory health. The inflammatory health measure is then augmented with personalized health interventions to improve and extend healthspan. Edifice has solid underpinnings in immunological science and in AI-powered technology. It will combine these proprietary elements with a consumer and market-centric orientation to deliver on its mission in tackling chronic diseases worldwide.

HiFiBiO is a biotherapeutics company that mobilizes the human immune system to combat disease. It commercializes proprietary single-cell technologies for applications in drug and biomarker discovery and development. It also aspires to benefit patients through open-innovation partnerships with industry and academia. HiFiBiO integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company was founded in 2013 and is headquartered in Paris, Ille-de-France.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Aelan Cell Technologies is actively looking for opportunities to partner with industry leaders that share similar goals. It is engaged in the research, discovery, development, and commercialization of innovative biomedical technologies for the advancement of human health and longevity.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Bracco Imaging SpA manufactures and develops diagnostic imaging solutions for public and private hospitals, imaging centers and private practices. The firm's services include radiology, X-ray imaging, magnetic resonance imaging and ultrasound applications. The company was founded in 1985 and is headquartered in Milan, Italy.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. The company was originally founded in 1851 by Ernst Christian Friedrich Schering. The company employs more than 26,000 people in 140 subsidiaries all over the world. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion. They retain the largest German manufacturing facility which is located in Bergkamen. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. Schering's best-known product is their line of combined oral contraceptive pills. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations.

Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It also sold insulin pumps controlled by microprocessors and various equipments to regulate heart rhythm. In addition, Cardiac Pacemakers, Inc. developed therapies for the treatment of irregular heartbeats. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. operates as a subsidiary of Boston Scientific Corporation.

Syntekabio is a Korean biotech firm, developing personal genome map which is expected to enable personalized medical service. The company also provides a technology for collecting and integrating decrypted whole genome data.

1st Biotherapeutics, Inc. engages in the manufacture of bio therapeutics products. Its products are mainly focused on Immuno-oncology, Neurodegenerative and Orphan Diseases. The company was founded by Kim Jae-Eun on May 25, 2016 and is headquartered in Seongnam, South Korea.

4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacteria, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies novel bacteria that have a precise and evolved therapeutic effect. All of 4D's live biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D currently has a pipeline of 15 therapeutic programmes covering autoimmune diseases, CNS disorders and cancer; with two programmes in patient trials, and the expectation to initiate another three programmes over the coming twelve months.

Flagship Biosciences, Inc. engages in medical and biological research. It offers drug development support, including target validation and hypothesis generation, exploratory and efficacy endpoints, predictive strategy building and companion diagnostics.The company was founded by G. David Young in 2009 and is headquartered in Broomfield, CO.

Berg is a Swiss private company located in Berg, with subsidiaries in Spain, providing investment services.

Plaxgen is a biodiagnostics company with a unique diagnostic platform to personalized medicine. We are focused on developing innovative technology for clinical diagnostics and the discovery of effective therapeutics to treat a broad spectrum of plaque-related diseases, including Alzheimer’s disease (AD) and atherosclerosis. Plaxgen’s proprietary Plaque Array platform was developed to detect and characterize serum-derived particles containing cholesterol or amyloid beta protein (abeta), tau and α-synuclein.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

IncellDx, Inc. detects and monitors life threatening diseases. It offers transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company was founded by Bruce K. Patterson and Carol Penfold-Patterson on December 3, 2009 and is headquartered in Menlo Park, CA.